pharmaphorum August 26, 2024
Phil Taylor

Siemens Healthineers has agreed a €200 million ($224 million) deal to buy the diagnostic arm of Novartis’ Advanced Accelerator Applications (AAA) radiopharma unit, boosting its medical imaging business.

The deal – originally reported by the Financial Times and confirmed by Novartis and Siemens Healthineers over the weekend without giving the value of the transaction – would leave Novartis holding only the radiotherapeutics operations of AAA, which it bought for $3.9 billion in 2017 to underpin its move into the radiopharma category.

The Swiss pharma group said it would continue to work with Siemens Healthineers to support and supply its radioligand therapies (RLTs), which include Lutathera (lutetium [Lu177] dotatate) for GEP-NET tumours, prostate cancer treatment Pluvicto (lutetium [Lu177] vipivotide tetraxetan), and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Medical Devices, Mergers & Acquisitions / JV, Trends
UN warns of military brain control
Only 20% of AI devices for children used pediatric data to train: 3 notes
Medtech firms have cut thousands of jobs this year. Will layoffs continue in 2025?
Proton therapy market in the US projected to reach $2.67 billion by 2033
How Trump’s second term will affect the medtech industry

Share This Article